GoodFellas Big Board Catalyst and Chart Plays

[xtremezz]

SOMX announces settlement of Silenor patent litigation with Actavis

Up in AH, though trading sparse.

Co has entered into a settlement agreement with Actavis Elizabeth and Actavis (ACT) to resolve pending patent litigation involving Silenor 3 mg and 6 mg tablets. The settlement agreement grants Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. The settlement agreement will become effective upon the entry by the U.S. District Court for the District of Delaware of an order dismissing the litigation with respect to Actavis.